1-3 of 3
Abraham Jacob
Close
Sort by
Journal Articles

Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia

Wojciech Jurczak, Andrzej Pluta, Malgorzata Wach, Daniel Lysak, Tomas Kozak, Martin Šimkovič, Iryna Kriachok, Arpad Illes, Javier de la Serna, Sean Dolan, Philip Campbell, Gerardo Musuraca, Abraham Jacob, Eric J. Avery, Jae Hoon Lee, Min Hui Wang, Ting Yu, Paolo Ghia
Journal: Blood
Blood (2021) 138 (Supplement 1): 393.
https://doi.org/10.1182/blood-2021-146570
Published: 2021
Journal Articles

Updated Analysis of Overall Survival in Randomized Phase III Study of Idelalisib in Combination with Bendamustine and Rituximab in Patients with Relapsed/Refractory CLL

Andrew D. Zelenetz, Jennifer R. Brown, Julio Delgado, Herbert Eradat, Paolo Ghia, Abraham Jacob, Wojciech Jurczak, Javier Loscertales, Donald MacDonald, Franck Morschhauser, Javier De la Serna, Mazyar Shadman, Christopher Pocock, Adeboye Henry Adewoye, Yeonhee Kim, David Simpson, Stephan Stilgenbauer
Journal: Blood
Blood (2016) 128 (22): 231.
https://doi.org/10.1182/blood.V128.22.231.231
Published: 2016
Journal Articles

Imatinib Resistance Mutation Analysis Pattern In Chronic Myeloid Leukemia (CML) Patients on Imatinib In Indian Population.

Mukul Goyal, MD, K.C. Lakshmaiah, MD, DM, K.Govind Babu, MD, DM, Amit Rauthan, MD, DM, Linu Abraham Jacob, MD, DM, Singh Tejinder, MD, DM, L.K. Rajeev, MD, G.Mehar Kumar, MD, Vineetha Unnikrishnan, MD
Journal: Blood
Blood (2010) 116 (21): 4491.
https://doi.org/10.1182/blood.V116.21.4491.4491
Published: 2010